As illustrated in Fig. 2A, our pan-cancer analysis unveiled a conspicuous upregulation of EVI2A expression not only in KIRC but also in other malignancies such as breast cancer (BRCA), Head and Neck Squamous Cell Carcinoma (HNSC), Cholangiocarcinoma (CHOL), and Kidney Renal Papillary Cell Carcinoma (KIRP). Here, EVI2A is linked to invasive breast carcinoma.